par8o has announced the launch of par8o Research Network (PRN), a clinical trial recruitment service that connects health center patients with nearby trials. To ensure both HIPAA and ethical compliance, par8o’s patient outreach and engagement protocol has been reviewed and approved by an independent Institutional Review Board, WCG IRB. With the launch of PRN, par8o will apply its knowledge to solve a major issue in clinical trials—specifically, the lack of racial, ethnic, and socioeconomic diversity.
“The lack of diversity in clinical research not only increases drug costs due to failed recruitment targets and delayed timelines, but also creates an ongoing legacy of healthcare injustice against minority groups,” said par8o CEO, Dr. Daniel Palestrant, MD. “It’s well known that different racial and ethnic groups can respond differently to the same treatments. Under-representation of minority groups in a clinical trial can create a legacy of bad data, which can ultimately impact patient access to therapeutics. We are confident that PRN will move the needle on the lack of diverse racial and ethnic representation in clinical trials.”
Read more in the full release, here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.